MP24-19 TYPE OF ANDROGEN DEPRIVATION THERAPY AND THE RISK OF CARDIOVASCULAR DISEASES IN PATIENTS WITH PROSTATE CANCER WITH OR WITHOUT PRE-EXISTING CARDIOVASCULAR RISK
Notice bibliographique
Résumé
You have accessJournal of UrologyProstate Cancer: Advanced (including Drug Therapy) II (MP24)1 Sep 2021MP24-19 TYPE OF ANDROGEN DEPRIVATION THERAPY AND THE RISK OF CARDIOVASCULAR DISEASES IN PATIENTS WITH PROSTATE CANCER WITH OR WITHOUT PRE-EXISTING CARDIOVASCULAR RISK Alice Dragomir, Nawar Touma, and Armen Aprikian Alice DragomirAlice Dragomir More articles by this author , Nawar ToumaNawar Touma More articles by this author , and Armen AprikianArmen Aprikian More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002015.19AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Controversies exist regarding the risk of cardiovascular events in prostate cancer patients treated with androgen deprivation therapy (ADT). We sought to evaluate the association between gonadotropin-releasing hormone (GnRH) agonists versus GnRH antagonist (Degarelix) and the risk of cardiovascular disease (CVD) in patients with prostate cancer with or without prior CVD. METHODS: Using administrative databases from the province of Quebec in Canada, we identified patients initiating androgen deprivation therapy (ADT) between Jan 2012 and June 2016. Two groups of patients were defined based on the type of ADT received at the 1st prescription: GnRH agonists and Degarelix groups. To be included, patients had to be new users of ADT. The end of follow-up was the date of the first CVD (myocardial infarction (MI), stroke, ischemic heart disease (IHD), arrhythmia and heart failure (HF)), switch of GnRH group, death or Dec 13, 2016. The inverse probability of treatment weighting (IPTW) based on propensity score was used to reduce the effect of potential confounding. IPTW-Cox proportional hazard model for competing risk was used to evaluate the association between the exposure to GnRH agonists or antagonist, and the risk of CVD. RESULTS: This study cohort consists of 10,785 patients: 10,201 initiating GnRH agonists and 584 initiating Degarelix. Mean age was 75 years old, similar between groups. A total of 3,304 (32.4%) and 236 (40.4%) men had CVD in the year prior to ADT initiation, in GnRH agonists and antagonist groups, respectively. A decreased risk of MI, stroke and HF was observed in Degarelix group, yet the Hazard ratios (HR) were not significant (HR: 0.63; 95% confidence interval (CI) 0.37-1.07, HR: 0.76; 95%CI 0.42-1.37 and HR: 0.64; 95%CI 0.41-1.00, respectively). But, an increased risk of arrhythmia was observed (HR:1.46; 95%CI 1.18-1.81) in Degarelix group when compared to the GnRH agonist group. CONCLUSIONS: Degarelix was found to be associated with the risk of developing arrhythmia compared to GnRH agonists in patients with prostate cancer regardless of pre-existing cardiovascular risk. Yet, it might be associated with a decreased risk for other CVDs in this population. Source of Funding: None © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e419-e419 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Alice Dragomir More articles by this author Nawar Touma More articles by this author Armen Aprikian More articles by this author Expand All Advertisement Loading ...
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction machine sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Le volet Gemma est une étiquette directe du modèle pour chaque travail de la base, lue sur la notice réduite au titre. Le volet Codex est un classifieur appris des 10 348 étiquettes directes de Codex et calibré sur les taux pondérés de l'échantillon; les champs sans appui suffisant ne portent aucun appel Codex. Le mode candidate est l'union des deux volets; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont pas des étiquettes humaines.
Scores du classifieur distillé par catégorie (deux têtes)
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,000 | 0,001 |
| Méta-épidémiologie (sens strict) | 0,000 | 0,000 |
| Méta-épidémiologie (sens large) | 0,000 | 0,000 |
| Bibliométrie | 0,001 | 0,001 |
| Études des sciences et des technologies | 0,001 | 0,000 |
| Communication savante | 0,000 | 0,000 |
| Science ouverte | 0,000 | 0,000 |
| Intégrité de la recherche | 0,000 | 0,001 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,003 | 0,000 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule source (Gemma direct ou Codex distillé), pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».